Cover Image
市場調查報告書

癌症免疫療法 (IO)的策略性考察:適應症、市場規模分析

Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis

出版商 GlobalData 商品編碼 363617
出版日期 內容資訊 英文 423 Pages
訂單完成後即時交付
價格
Back to Top
癌症免疫療法 (IO)的策略性考察:適應症、市場規模分析 Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis
出版日期: 2016年05月01日 內容資訊: 英文 423 Pages
簡介

全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的癌症免疫療法 (IO)的市場,2019年約成長到140億美元,2024年達340億美元的規模。尤其是免疫查核點抑制劑預計帶動該市場的成長,其銷售額規模預計從2019年的約100億美元,成長到2024年的240億美元。

本報告提供癌症免疫療法 (IO)的市場調查,IO的發展過程,技術、產品的分類及概要,主要藥物、開發平台分析,各適應症的收益預測,企業策略分析等彙整資料。

第1章 目錄

第2章 簡介

第3章 IO的發展

  • IO的發展的過程
  • 近幾年的IO的認證時間軸
  • IO產品的分類

第4章 技術、產品概要

  • 查核點調製器
    • 作用機制
    • 臨床概要
    • Opdivo (Nivolumab)
    • Keytruda (Pembrolizumab)
    • Atezolizumab
    • Durvalumab and Tremelimumab
    • Avelumab
    • Yervoy (Ipilimumab)
  • 細胞免疫療法
    • 樹突狀細胞療法
    • CAR-T療法
    • 銷售額估計
    • SWOT分析
  • 癌症疫苗
    • NeuVax
    • HyperAcute-Pancreas
    • ProstVac
    • Vigil
    • 其他後期開發階段的疫苗
    • 銷售額估計
    • SWOT分析
  • 腫瘤溶解性病毒
    • Imlygic (Talimogene laherparepvec)
    • ProstAtak
    • 其他後期開發階段的腫瘤溶解性病毒
    • 銷售額估計
    • SWOT分析
  • BiTE (Bispecific T-cell Engager)
    • Blincyto (Blinatumomab)
  • 其他後期開發階段的產品
    • Empliciti (Elotuzumab)

第5章 各適應症分析

  • 急性白血病
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 膀胱癌
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 乳癌
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 慢性白血病
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 大腸癌
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 胃腺癌、胃接處腺癌
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 神經膠質母細胞瘤
    • 疾病概要
    • 目前治療方法
    • IO的發展
    • 非免疫療法
  • 頭頸椎鱗狀細胞癌
    • 疾病概要
    • 目前治療方法
    • IO的發展
    • 非免疫療法
  • 肝癌
    • 疾病概要
    • 目前治療方法
    • IO的發展
    • 非免疫療法
  • 黑色素瘤
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 多發性骨髓瘤
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 非何杰金氏淋巴瘤
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 非小細胞肺癌
    • 疾病概要
    • 目前治療方法
    • IO的發展
    • 非免疫療法
  • 卵巢癌
    • 疾病概要
    • 目前治療方法
    • IO的發展
    • 非免疫療法
  • 胰臟癌
    • 疾病概要
    • 目前治療方法
    • IO的發展
    • 非免疫療法
  • 前列腺癌
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法
  • 腎細胞癌
    • 疾病概要
    • 目前治療範例、演算法
    • IO的發展
    • 非免疫療法

第6章 企業策略

  • 聯合治療
  • 生物標記
  • 契約

第7章 附錄

圖表

目錄
Product Code: GDHC057POA

GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion and $7 billion, respectively. This is because these two drugs will be first-to-market in many indications, leapfrogging competition such as Roche's atezolizumab and AstraZeneca's durvalumab.

Highlights

Key Questions Answered

  • Development of IO Products has increased significantly in the past three years. Which IO approaches will be the most commercially successful? Which early-stage IO approaches show the most promise?
  • Novel combinations will differentiate late-to-market entrants. Which combinations are the most promising for each cancer type? What strategies are IO developers utilizing to differentiate themselves in this crowded market? What collaborations and deals are the most promising?
  • NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024. Which diseases are going to be the biggest contributors to the IO market. Which IO product will be the most commercially successful in each disease? Which clinical and commercial strategies are IO developers pursuing in each disease?

Key Findings

  • Opdivo will be the biggest selling IO drug by 2024, with approval forecast in seven indications
  • Keytruda will be the second biggest selling IO drug by 2024, with approval forecast in eight indications
  • NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024
  • Novel combinations will allow late-to-market entrants such as durvalumab to achieve significant sales

Scope

  • Overview of IO approaches, including checkpoint inhibitors, cell therapies, peptide vaccines, oncolytic viruses, bi-specific antibodies and CAR-T therapies.
  • Revenue by indications for major IO products in 2019 and 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the IO therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global IO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. This include analysis of novel combinations and the role of biomarkers such as PD-L1

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. IO Development

  • 3.1. History of IO Development
  • 3.2. Recent Timeline of IO Approvals
  • 3.3. IO Product Classification

4. Technology and Product Overview

  • 4.1. Checkpoint Modulators
    • 4.1.1. Mechanism of Action
    • 4.1.2. Clinical Overview
    • 4.1.3. Opdivo (Nivolumab)
    • 4.1.4. Keytruda (Pembrolizumab)
    • 4.1.5. Atezolizumab
    • 4.1.6. Durvalumab and Tremelimumab
    • 4.1.7. Avelumab
    • 4.1.8. Yervoy (Ipilimumab)
  • 4.2. Cellular Immunotherapies
    • 4.2.1. Dendritic Cell Therapies
    • 4.2.2. CAR-T Therapies
    • 4.2.3. Sales Estimate
    • 4.2.4. SWOT Analysis
  • 4.3. Cancer Vaccines
    • 4.3.1. NeuVax
    • 4.3.2. HyperAcute-Pancreas
    • 4.3.3. ProstVac
    • 4.3.4. Vigil
    • 4.3.5. Other Late-Stage Vaccines
    • 4.3.6. Sales Estimate
    • 4.3.7. SWOT Analysis
  • 4.4. Oncolytic Viruses
    • 4.4.1. Imlygic (Talimogene laherparepvec)
    • 4.4.2. ProstAtak
    • 4.4.3. Other Late-Stage Oncolytic Viruses
    • 4.4.4. Estimated Sales
    • 4.4.5. SWOT Analysis
  • 4.5. Bispecific T-cell Engagers
    • 4.5.1. Blincyto (Blinatumomab)
  • 4.6. Other Late-Stage Immuno-oncology Products
    • 4.6.1. Empliciti (Elotuzumab)

5. Indication-Specific Analysis

  • 5.1. Acute Leukemias
    • 5.1.1. Disease Overview
    • 5.1.2. Current Treatment Paradigm and Algorithm
    • 5.1.3. IO Development
    • 5.1.4. Non-Immunotherapy Threats
  • 5.2. Bladder Cancer
    • 5.2.1. Disease Overview
    • 5.2.2. Current Treatment Paradigm and Algorithm
    • 5.2.3. IO Development
    • 5.2.4. Non-immunotherapy Threats
  • 5.3. Breast Cancer
    • 5.3.1. Disease Overview
    • 5.3.2. Current Treatment Paradigm and Algorithm
    • 5.3.3. IO Development
    • 5.3.4. Non-immunotherapy Threats
  • 5.4. Chronic Leukemias
    • 5.4.1. Disease Overview
    • 5.4.2. Current Treatment Paradigm and Algorithm
    • 5.4.3. IO Development
    • 5.4.4. Non-immunotherapy Threats
  • 5.5. Colorectal Cancer
    • 5.5.1. Disease Overview
    • 5.5.2. Current Treatment Paradigm and Algorithm
    • 5.5.3. IO Development
    • 5.5.4. Non-immunotherapy Threats
  • 5.6. Gastric and Gastroesophageal Junction Adenocarcinoma
    • 5.6.1. Disease Overview
    • 5.6.2. Current Treatment Paradigm and Algorithm
    • 5.6.3. IO Development
    • 5.6.4. Non-immunotherapy Threats
  • 5.7. Glioblastoma
    • 5.7.1. Disease Overview
    • 5.7.2. Current Treatments
    • 5.7.3. IO Development
    • 5.7.4. Non-immunotherapy Treatments
  • 5.8. Head and Neck Squamous Cell Carcinoma
    • 5.8.1. Disease Overview
    • 5.8.2. Current Treatments
    • 5.8.3. IO Development
    • 5.8.4. Non-immunotherapy Threats
  • 5.9. Hepatocellular Carcinoma
    • 5.9.1. Disease Overview
    • 5.9.2. Current Treatments
    • 5.9.3. IO Development
    • 5.9.4. Non-immunotherapy Threats
  • 5.10. Melanoma
    • 5.10.1. Disease Overview
    • 5.10.2. Current Treatment Paradigm and Algorithm
    • 5.10.3. IO Development
    • 5.10.4. Non-immunotherapy Treatments
  • 5.11. Multiple Myeloma
    • 5.11.1. Disease Overview
    • 5.11.2. Current Treatment Paradigm and Algorithm
    • 5.11.3. IO Development
    • 5.11.4. Non-immunotherapy Threats
  • 5.12. Non-Hodgkin's Lymphoma
    • 5.12.1. Disease Overview
    • 5.12.2. Current Treatment Paradigm and Algorithm
    • 5.12.3. IO Development
    • 5.12.4. Non-immunotherapy Treatments
  • 5.13. Non-small Cell Lung Cancer
    • 5.13.1. Disease Overview
    • 5.13.2. Current Treatments
    • 5.13.3. IO Development
    • 5.13.4. Non-immunotherapy Threats
  • 5.14. Ovarian Cancer
    • 5.14.1. Disease Overview
    • 5.14.2. Current Treatments
    • 5.14.3. IO Development
    • 5.14.4. Non-immunotherapy Threats
  • 5.15. Pancreatic Cancer
    • 5.15.1. Disease Overview
    • 5.15.2. Current Treatments
    • 5.15.3. IO Development
    • 5.15.4. Non-immunotherapy Threats
  • 5.16. Prostate Cancer
    • 5.16.1. Disease Overview
    • 5.16.2. Current Treatment Paradigm and Algorithm
    • 5.16.3. IO Development
    • 5.16.4. Non-immunotherapy Threats
  • 5.17. Renal Cell Carcinoma
    • 5.17.1. Disease Overview
    • 5.17.2. Current Treatment Paradigm and Algorithm
    • 5.17.3. IO Development
    • 5.17.4. Non-immunotherapy Threats

6. Company Strategies

  • 6.1. Combinations
    • 6.1.1. Combination Type and Development Phase
    • 6.1.2. Immunotherapy Combinations by Cancer Type
    • 6.1.3. Immunotherapy Combinations by Approach
    • 6.1.4. Immunotherapy Combinations by Target
    • 6.1.5. Immunotherapy Combinations in Phase III Development (IO + IO)
    • 6.1.6. Major IO Products in Combination Therapy
  • 6.2. Biomarkers
    • 6.2.1. Overview
    • 6.2.2. PD-L1 Biomarker
    • 6.2.3. Microsatellite Instability and Mutational Load
    • 6.2.4. Human Leukocyte Antigen Alleles
  • 6.3. Deals

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. IO Product and Trial Identification Methodology
    • 7.3.1. Inclusion Criteria for IO Products
    • 7.3.2. Exclusion Criteria for IO Products
    • 7.3.3. Classification of IO Approach
    • 7.3.4. List of Trials Involving IO Products
  • 7.4. List of IO Drugs
  • 7.5. Forecasting Methodology
    • 7.5.1. Launch Dates
    • 7.5.2. Sales Estimates
  • 7.6. About the Authors
    • 7.6.1. Lead Analyst
    • 7.6.2. Analysts
    • 7.6.3. Therapy Area Director
    • 7.6.4. Global Director of Therapy Analysis and Epidemiology
    • 7.6.5. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Opdivo SWOT Analysis
  • Table 2: Keytruda SWOT Analysis
  • Table 3: Atezolizumab SWOT Analysis
  • Table 4: Durvalumab and Tremelimumab SWOT Analysis
  • Table 5: Avelumab SWOT Analysis
  • Table 6: Yervoy SWOT Analysis
  • Table 7: IO Cell Therapies SWOT Analysis
  • Table 8: Cancer Vaccines SWOT Analysis
  • Table 9: Oncolytic Viruses SWOT Analysis
  • Table 10: Approved IO Drugs and Combinations for Advanced Melanoma
  • Table 11: Approved BRAF/MEK-Targeting Drugs and Combinations for BRAF-Mutated Advanced Melanoma
  • Table 12: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum
  • Table 13: Treatment Guidelines for Ovarian Cancer in the 7MM
  • Table 14: IO + IO Combinations in Phase III Clinical Development
  • Table 15: PD-L1 Testing Criteria in NSCLC and Clinical Efficacy
  • Table 16: List of Immuno-oncology Drugs

List of Figures

  • Figure 1: Typical Kaplan-Meier Plot for Chemotherapy, Targeted Therapy, IO, and IO Combinations
  • Figure 2: Timeline of All IO Products Approved
  • Figure 3: Development of Opdivo Across Oncology Indications
  • Figure 4: Timeline of Approvals/Estimated Approvals for Opdivo
  • Figure 5: Overview of Selected Opdivo Late-Stage Trials
  • Figure 6: Opdivo Sales Estimate for 2019 and 2024
  • Figure 7: Development of Keytruda Across Oncology Indications
  • Figure 8: Timeline of Approvals/Estimated Approvals for Keytruda
  • Figure 9: Overview of Selected Keytruda Late-Stage Trials
  • Figure 10: Keytruda Sales Estimate for 2019 and 2024
  • Figure 11: Development of Atezolizumab Across Oncology Indications
  • Figure 12: Timeline of Approvals/Estimated Approvals for Atezolizumab
  • Figure 13: Overview of Selected Atezolizumab Late-Stage Trials
  • Figure 14: Atezolizumab Sales Estimate for 2019 and 2024
  • Figure 15: Development of Durvalumab Across Oncology Indications
  • Figure 16: Development of Tremelimumab Across Oncology Indications
  • Figure 17: Timeline of Approvals/Estimated Approvals for Durvalumab (with Tremelimumab)
  • Figure 18: Overview of Selected Durvalumab Late-Stage Trials
  • Figure 19: Durvalumab Sales Estimate for 2019 and 2024
  • Figure 20: Tremelimumab Sales Estimate for 2019 and 2024
  • Figure 21: Development of Avelumab Across Oncology Indications
  • Figure 22: Timeline of Approvals/Estimated Approvals for Avelumab
  • Figure 23: Overview of Selected Avelumab Late-Stage Trials
  • Figure 24: Avelumab Sales Estimate for 2019 and 2024
  • Figure 25: Development of Yervoy Across Oncology Indications
  • Figure 26: Timeline of Approvals/Estimated Approvals for Yervoy
  • Figure 27: Overview of Selected Yervoy Late-Stage Trials
  • Figure 28: Yervoy Sales Estimate for 2019 and 2024
  • Figure 29: IO Cell Therapies Sales Estimate for 2019 and 2024
  • Figure 30: Cancer Vaccines Sales Estimate for 2019 and 2024
  • Figure 31: Oncolytic Virus Sales Estimate for 2019 and 2024
  • Figure 32: Bispecific T-Cell Engagers Sales Estimate for 2019 and 2024
  • Figure 33: Empliciti Sales Estimate for 2019 and 2024
  • Figure 34: Treatment Flow Chart for ALL Patients
  • Figure 35: Treatment Flow Chart for AML Patients
  • Figure 36: Overview of Main IO Approaches, Targets, and Trial Development in ALL Patients
  • Figure 37: Overview of Main IO Approaches, Targets, and Trial Development in AML Patients
  • Figure 38: Approval Timeline for IO Drugs in ALL Patients
  • Figure 39: An Overview of the Late-Stage Trials with IO Products in ALL Patients
  • Figure 40: An Overview of the Late-Stage Trials with IO Products in AML Patients
  • Figure 41: An Overview of the Early-Stage Trials with IO Products in ALL Patients
  • Figure 42: An Overview of the Early-Stage Trials with IO Products in AML Patients
  • Figure 43: Non-Immunotherapy Treatments in ALL Patients
  • Figure 44: Non-Immunotherapy Treatments in AML Patients
  • Figure 45: Treatment Flow Chart for Bladder Cancer Patients
  • Figure 46: Overview of Immuno-oncology Development in Bladder Cancer
  • Figure 47: Phase III Timeline in Bladder Cancer
  • Figure 48: Phase III Trials in Bladder Cancer
  • Figure 49: Overview of the Early-Stage IO Trials in Bladder Cancer Patients
  • Figure 50: Non-immunotherapy Threats in Bladder Cancer
  • Figure 51: Treatment Flow Chart for Stage 0-III Breast Cancer Patients
  • Figure 52: Treatment Flow Chart for Stage IV or Recurrent Breast Cancer Patients
  • Figure 53: Overview of IO Development in Breast Cancer
  • Figure 54: Current Phase III Timeline in Breast Cancer
  • Figure 55: Late-Stage Pivotal Trials in Breast Cancer Patients
  • Figure 56: Overview of the Early-Stage IO Trials in Breast Cancer Patients
  • Figure 57: Non-immunotherapy Threats in Breast Cancer
  • Figure 58: Treatment Flow Chart for CLL Patients
  • Figure 59: Treatment Flow Chart for CML Patients
  • Figure 60: Overview of Main IO Approaches, Targets, and Trial Development in CLL Patients
  • Figure 61: Overview of Main IO Approaches, Targets, and Trial Development in CML Patients
  • Figure 62: An Overview of the Late-Stage Trials with IO Products in CLL Patients
  • Figure 63: An Overview of the Late-Stage Trials with IO Products in CML Patients
  • Figure 64: An Overview of the Early-Stage Trials with IO Products in CLL Patients
  • Figure 65: An Overview of the Early-Stage Trials with IO Products in CML Patients
  • Figure 66: Non-immunotherapy Treatments in CLL Patients
  • Figure 67: Non-Immunotherapy Treatments in CML Patients
  • Figure 68: Treatment Flow Chart for CRC Patients
  • Figure 69: Overview of Main IO Approaches, Targets, and Trial Development in CRC Patients
  • Figure 70: Current Phase III and Regulatory Approval Timeline in CRC
  • Figure 71: An Overview of the Late-Stage Trials with IO Products in CRC Patients
  • Figure 72: An Overview of the Early-Stage Trials with IO Products in CRC Patients
  • Figure 73: Non-immunotherapy Treatments in CRC Patients
  • Figure 74: Treatment Flow Chart for Advanced G/GEJAC Patients
  • Figure 75: Overview of IO Development in G/GEJAC
  • Figure 76: Current Phase III Timeline in G/GEJAC
  • Figure 77: Late-Stage Pivotal IO Trials in G/GEJAC Patients
  • Figure 78: Selected Early-Stage IO Trials in G/GEJAC Patients
  • Figure 79: Non-immunotherapy Threats in G/GEJAC
  • Figure 80: Treatment Flow Chart for GBM Patients
  • Figure 81: Overview of Immunotherapies in Glioblastoma
  • Figure 82: Current Phase III Timeline in GBM
  • Figure 83: Late-Stage Pivotal IO Trials in GBM Patients
  • Figure 84: Overview of Selected Trials in GBM Patients
  • Figure 85: Non-immunotherapy Treatments in GBM
  • Figure 86: Treatment Flow Chart for HNSCC Patients
  • Figure 87: Overview of IO Development in HNSCC
  • Figure 88: Current Phase III Timeline in HNSCC
  • Figure 89: Late-Stage Pivotal IO Trials in HNSCC Patients
  • Figure 90: Overview of Early-Stage IO Trials in HNSCC Patients
  • Figure 91: Non-immunotherapy Threats in HNSCC
  • Figure 92: HCC Treatment Regimen by BCLC Stage
  • Figure 93: Overview of Immuno-oncology Development in HCC
  • Figure 94: Phase III Timeline in HCC
  • Figure 95: Phase III Trials in HCC
  • Figure 96: Overview of the Early-Stage IO Trials in HCC Patients
  • Figure 97: Non-immunotherapy Threats in HCC
  • Figure 98: Current Flowchart for Melanoma
  • Figure 99: Overview of IO Development in Melanoma
  • Figure 100: Current Phase III Timeline in Melanoma
  • Figure 101: Late-Stage Pivotal IO Trials in Melanoma Patients
  • Figure 102: Immune Checkpoint Modulator Combinations in Early-Stage Development
  • Figure 103: Non-immunotherapy Threats in Melanoma
  • Figure 104: Treatment Flow Chart for Multiple Myeloma Patients
  • Figure 105: Overview of Immunotherapies in Multiple Myeloma
  • Figure 106: Current Phase III Timeline in Multiple Myeloma
  • Figure 107: Late-Stage Pivotal IO Trials in Multiple Myeloma Patients
  • Figure 108: Selected Early-Stage Pivotal IO Trials in Multiple Myeloma Patients
  • Figure 109: Non-immunotherapy Treatments in Multiple Myeloma
  • Figure 110: Treatment Algorithm for NHL Patients
  • Figure 111: IO Approaches, Targets, and Clinical Trials in NHL Patients
  • Figure 112: Current Regulatory Approval Timeline in NHL
  • Figure 113: Late-Stage IO Trials in NHL Patients
  • Figure 114: Overview of Early-Stage IO Trials in NHL Patients
  • Figure 115: Non-immunotherapy Threats in NHL
  • Figure 116: Treatment Flow Chart for Stage III/IV NSCLC Patients
  • Figure 117: Overview of Main IO Approaches, Targets, and Trial Development in NSCLC Patients
  • Figure 118: Current Phase III Timeline in NSCLC
  • Figure 119: An Overview of the Late-Stage Trials with IO Products in NSCLC Patients
  • Figure 120: Overview of the Early-Stage IO Trials in NSCLC Patients
  • Figure 121: Non-immunotherapy Treatments in NSCLC
  • Figure 122: Top-Level Treatment Flow Chart for Ovarian Cancer Patients
  • Figure 123: Ovarian Cancer IO Products in Development by Therapeutic Approach
  • Figure 124: IO Products in Late-Stage Development for Ovarian Cancer-Estimated Approval Dates
  • Figure 125: IO Products in Late-Stage Development for Ovarian Cancer-Pivotal Clinical Trials
  • Figure 126: IO Products in Early-Stage Development for Ovarian Cancer
  • Figure 127: Non-IO Therapies Recently Approved or in the Late-Stage Ovarian Cancer Pipeline
  • Figure 128: Treatment Flow Chart for Pancreatic Cancer Patients
  • Figure 129: Overview of Immunotherapies in Pancreatic Cancer
  • Figure 130: Estimated Approval Times for Immunotherapies in Pancreatic Cancer
  • Figure 131: Current Phase III Trials in Pancreatic Cancer
  • Figure 132: Selected Early-Phase IO Trials in Pancreatic Cancer
  • Figure 133: Non-immunotherapy Treatments in Pancreatic Cancer
  • Figure 134: Treatment Flow Chart for Prostate Cancer Patients
  • Figure 135: Overview of Main IO Approaches, Targets, and Trial Development in Prostate Cancer Patients
  • Figure 136: Current Phase III and Regulatory Approval Timeline in Prostate Cancer Patients
  • Figure 137: An Overview of the Late-Stage Trials with IO Products in Prostate Cancer Patients
  • Figure 138: An Overview of the Early-Stage IO Trials in Prostate Cancer Patients
  • Figure 139: Non-immunotherapy Treatments in Prostate Cancer Patients
  • Figure 140: Treatment Algorithm for Advanced RCC Patients
  • Figure 141: IO Approaches, Targets, and Clinical Trials in RCC Patients
  • Figure 142: Current Phase III and Regulatory Approval Timeline in RCC
  • Figure 143: Late-Stage IO Trials in RCC Patients
  • Figure 144: Early-Stage IO Trials in RCC Patients
  • Figure 145: Non-immunotherapy Threats in RCC
  • Figure 146: Clinical Development Activity by Combination Type and Development Phase
  • Figure 147: Clinical Development Activity by Combination and Cancer Type
  • Figure 148: Clinical Development Activity by Combination Type and Approach
  • Figure 149: Clinical Development Activity by Combination Type and Target
  • Figure 150: Select IO Products in Clinical Development by Combination Type
  • Figure 151: Select Keytruda IO Combinations in Clinical Development by Combination Type
  • Figure 152: Select Opdivo/Yervoy Combinations in Clinical Development by Combination Type
  • Figure 153: Select Durvalumab/Tremelimumab IO Combinations in Clinical Development by Combination Type
  • Figure 154: Select Atezolizumab IO Combinations in Clinical Development by Combination Type
  • Figure 155: Number of Trials Tagged for PD-L1 Biomarker Positivity
  • Figure 156: Number of Trials Tagged for HLA-A2/A1 Positivity
  • Figure 157: Number of Deals by IO Products
Back to Top